Second Generation, Anti-Cholesterol Drug Candidate To Lower Cholesterol And
Raise HDL (Good Cholesterol)
Early preliminary results for the ZPRO
Pharmaceutical, Inc. weight-loss supplement fiber Q-Slim (non-exclusive sale
license recently granted to ZORBA Nutraceuticals, Inc., see November 30, 2005
press release, http://www.prweb.com/releases/2005/11/prweb315974.htm) has led to
a second generation, very promising, new prescription drug candidate. This
candidate will now undergo further testing and seek FDA approval as a drug for
lowering cholesterol and triglyceride levels, while raising good cholesterol
(HDL) levels. Supplemental data from weight loss studies comparing Q-Slim to
CortiSlim and placebo control groups, surprising showed that participants taking
the Q-Slim supplement had lower cholesterol and lower triglycerides levels,
while raising their HDL cholesterol (good cholesterol) levels. This confirmed
that a second generation, more powerful composition known as Compound Z is also
likely to perform well as an anti-cholesterol FDA drug candidate. A 90 day human
study (double blind, where neither study providers nor study participants know
what they are taking) with Q-Slim is expected to conclude during late December
2005
Pharmaceutical, Inc. weight-loss supplement fiber Q-Slim (non-exclusive sale
license recently granted to ZORBA Nutraceuticals, Inc., see November 30, 2005
press release, http://www.prweb.com/releases/2005/11/prweb315974.htm) has led to
a second generation, very promising, new prescription drug candidate. This
candidate will now undergo further testing and seek FDA approval as a drug for
lowering cholesterol and triglyceride levels, while raising good cholesterol
(HDL) levels. Supplemental data from weight loss studies comparing Q-Slim to
CortiSlim and placebo control groups, surprising showed that participants taking
the Q-Slim supplement had lower cholesterol and lower triglycerides levels,
while raising their HDL cholesterol (good cholesterol) levels. This confirmed
that a second generation, more powerful composition known as Compound Z is also
likely to perform well as an anti-cholesterol FDA drug candidate. A 90 day human
study (double blind, where neither study providers nor study participants know
what they are taking) with Q-Slim is expected to conclude during late December
2005